Connecticut occupies a unique position in American healthcare. It is Aetna’s home state — the insurer was founded in Hartford in 1853 and maintained its headquarters there for more than 160 years before its acquisition by CVS Health. That history matters for pulmonary & critical care billing services in Connecticut because Aetna’s presence in the state is not simply large; it is foundational. Aetna is embedded in Connecticut’s employer market, individual market, Medicare Advantage landscape, and increasingly its Medicaid managed care program. For pulmonary practices in Hartford, New Haven, Bridgeport, Stamford, and throughout the state, managing this payer relationship effectively can have a significant impact on revenue cycle performance.
Managing Aetna billing effectively in Connecticut requires an understanding of a payer that is simultaneously one of the most sophisticated utilization management organizations in the country and one of the most demanding when it comes to documentation and prior authorization compliance. Aetna’s clinical policy bulletins, which help govern coverage decisions for pulmonary procedures and services, can be detailed and highly specific. The gap between what Aetna’s policies require and what many pulmonary practices’ standard billing workflows provide is where avoidable revenue leakage can occur.
For practices handling complex pulmonary and critical care claims, accurate documentation and coding are especially important. Comprehensive critical care coding & billing services can help practices identify documentation gaps, apply appropriate coding guidelines, manage payer-specific requirements, and reduce preventable claim denials. A structured billing workflow also helps ensure that prior authorization, medical necessity documentation, coding, claim submission, and denial follow-up are handled consistently.
This post examines Aetna’s specific prior authorization requirements for pulmonary services in Connecticut, the documentation standards that influence medical necessity decisions, the most common billing errors Connecticut pulmonary practices encounter with Aetna, and the workflow improvements that can help close revenue gaps.
Aetna in Connecticut: Understanding the Payer Landscape
Aetna operates multiple distinct product lines in Connecticut, each with different network configurations, benefit structures, and prior authorization requirements. The major Aetna product categories that Connecticut pulmonary practices encounter include fully insured commercial HMO and PPO products, self-funded employer plans administered under ASO arrangements, Medicare Advantage plans (including Aetna Medicare Advantage HMO and PPO products), and Aetna Better Health of Connecticut, the Medicaid managed care plan Aetna operates under contract with the Connecticut Department of Social Services.
The distinction between these product lines is clinically and operationally significant. Aetna’s fully insured commercial plans operate under Connecticut Insurance Department regulation and must follow Connecticut’s insurance laws, including the state’s utilization review and appeals requirements. Aetna’s ASO plans administering self-funded employer benefits are governed by ERISA, not Connecticut insurance law, and may have customized benefit designs and authorization requirements that differ from Aetna’s standard commercial policies. Aetna Medicare Advantage follows CMS rules for Medicare coverage with Aetna’s supplemental utilization management. And Aetna Better Health of Connecticut follows Connecticut Medicaid coverage policies with plan-level additions.
A pulmonary practice that applies a single Aetna billing workflow to patients across all of these product lines will systematically mishandle authorization requirements and documentation standards for at least some of them. The variation between product lines is not minor — it is material enough to be the primary driver of Aetna-related denials in many Connecticut pulmonary practices.
Aetna’s Prior Authorization Requirements for Pulmonary Services
Aetna requires prior authorization for a broader range of pulmonary procedures than most Connecticut practices realize, and the authorization requirements are enforced with a rigor that reflects Aetna’s sophisticated utilization management infrastructure. Procedures requiring authorization under Aetna’s Connecticut commercial plans include bronchoscopy and its advanced variants, endobronchial ultrasound, navigational bronchoscopy, pulmonary rehabilitation programs, polysomnography and home sleep apnea testing in certain clinical contexts, selected pulmonary function test sequences, and biologic therapies for asthma and COPD.
Aetna’s authorization requirements are documented in its Clinical Policy Bulletins (CPBs), which are publicly available on the Aetna provider portal and are updated on a rolling basis as clinical evidence evolves and coverage policies change. Connecticut pulmonary practices that do not actively monitor Aetna’s CPB updates will find their authorization workflows based on outdated policy — and will encounter denials for procedures they believed were routinely covered without authorization.
The Authorization Errors Connecticut Practices Make Most Often
The most costly Aetna authorization error in Connecticut pulmonary practices is the CPT scope mismatch: an authorization is obtained for the planned procedure, the procedure evolves during the encounter, and the additional components are billed without authorization coverage. Aetna’s authorization system is procedure-code specific — the authorization approval identifies the specific CPT codes covered. Claims for CPT codes not listed on the authorization are denied regardless of the clinical relationship between the planned and performed procedures.
For Connecticut pulmonary practices performing bronchoscopy — where the procedure frequently expands beyond the planned scope based on intraoperative findings — this is a recurring revenue loss. A diagnostic bronchoscopy that becomes a bronchoscopy with biopsy, or a standard bronchoscopy that incorporates lavage not included in the original authorization, generates additional billed CPT codes that are not on the authorization. Aetna denies the additional codes. The denial reason code looks like a medical necessity issue. The root cause is an authorization scope gap.
The second most common Aetna authorization error is applying standard commercial authorization requirements to ASO plan patients without confirming whether the ASO plan has customized requirements. Connecticut has a large number of small to mid-size employers — in insurance, financial services, manufacturing, and healthcare — many of whom self-fund their employee health benefits through ASO arrangements with Aetna. These employers may have more restrictive authorization requirements than Aetna’s standard commercial plan, particularly for high-cost specialty procedures.
A Connecticut pulmonary practice that obtains authorization for a bronchoscopy under Aetna’s standard commercial policy, without confirming that the specific employer’s ASO plan follows the same policy, may find that the authorization is not valid for that patient’s plan. The claim denies. The authorization confirmation number in the billing record is genuine — but it was issued under the wrong policy framework.
The prevention requires confirming at eligibility verification whether the patient is enrolled in a fully insured Aetna product or a self-funded ASO plan, and if ASO, confirming the specific plan’s authorization requirements before scheduling the procedure. This information is available through Aetna’s NaviMedix authorization portal and through the eligibility response to electronic eligibility inquiries, which identifies the plan funding type.
Aetna’s Medical Necessity Documentation Standards
Pulmonary Function Testing
Aetna’s clinical policy for pulmonary function testing requires that the ordering provider’s documentation establish the specific clinical indication for the testing, the patient’s relevant respiratory history and symptom progression, the results of prior diagnostic evaluation where applicable, and — for repeat or serial testing — the clinical rationale for why prior test results do not adequately answer the current clinical question.
Connecticut pulmonary practices consistently encounter Aetna medical necessity denials for PFTs when the clinical documentation references only a diagnosis code without the supporting narrative that Aetna’s reviewers are instructed to look for. A claim for pulmonary function testing with a diagnosis of COPD and a note that says “patient with COPD, spirometry ordered for monitoring” does not meet Aetna’s documentation standard for medical necessity. The note must explain what the testing will inform, how it relates to the patient’s current clinical trajectory, and why it is needed at this point in the patient’s care.
Sleep Diagnostics: HSAT vs. PSG in the Aetna Framework
Aetna’s coverage policy for sleep diagnostics is among the most detailed of any commercial payer in Connecticut. For home sleep apnea testing, Aetna requires that the ordering provider document a clinical evaluation consistent with a high pretest probability of obstructive sleep apnea, using a validated clinical tool such as the STOP-BANG questionnaire or the Epworth Sleepiness Scale in conjunction with clinical assessment. The documentation must reflect this structured evaluation — not merely a chief complaint of snoring or fatigue.
For in-laboratory polysomnography, Aetna’s Connecticut policy specifies the clinical circumstances under which PSG is preferred over HSAT: patients with significant cardiopulmonary disease, neuromuscular conditions affecting respiratory function, suspected non-OSA sleep disorders, or prior HSAT with inconclusive results. Ordering PSG for a patient who meets HSAT criteria — without documenting the clinical reason for preferring in-lab testing — will result in an Aetna downgrade to HSAT reimbursement or an outright denial of the PSG claim.
For CPAP titration and follow-up, Aetna requires documentation of the diagnostic study results, the patient’s adherence data at follow-up visits, and the clinical rationale for any treatment modifications. Follow-up visits for sleep-disordered breathing management that do not include objective adherence data — typically downloaded from the CPAP device — are frequently denied by Aetna as lacking medical necessity documentation.
Biologic Therapy Authorization: The Most Documentation-Intensive Category
Biologic therapies for severe asthma — including dupilumab (Dupixent), mepolizumab (Nucala), benralizumab (Fasenra), omalizumab (Xolair), and tezepelumab (Tezspire) — represent the highest-value authorization category in most Connecticut pulmonary practices’ billing operations. They also represent the most documentation-intensive authorization process in pulmonary medicine.
Aetna’s clinical policy bulletins for each biologic specify the exact documentation required for authorization: confirmed diagnosis of severe persistent asthma meeting specific severity criteria, failure of or contraindication to maximum tolerated doses of inhaled corticosteroids and at least one additional controller medication, relevant biomarker results (blood eosinophil count for anti-IL-5 agents, total IgE and allergen-specific IgE for omalizumab, FeNO measurement for dupilumab where applicable, no biomarker restriction for tezepelumab), and pulmonologist attestation of the clinical indication.
Each element of this documentation package must be present in the medical record at the time of authorization request. Missing biomarker results, incomplete step-therapy documentation, or pulmonologist attestation that does not address the specific criteria in Aetna’s CPB will result in authorization denial. Because biologic authorizations represent $15,000 to $40,000 or more in annual drug costs per patient, Aetna’s utilization management for these therapies is among the most rigorous it applies to any service category.
Connecticut pulmonary practices that manage significant severe asthma programs need a biologic authorization protocol that collects all required documentation before the authorization request is submitted — not after the first denial. A denial-and-appeal cycle for biologic authorizations delays patient access to therapy by weeks to months and consumes significant staff time on appeals that could have been prevented with a complete initial submission.
Aetna’s Appeal Process in Connecticut
Connecticut’s insurance regulatory framework provides significant protections for providers and patients in the appeal process. The Connecticut Insurance Department regulates Aetna’s fully insured products and requires compliance with Connecticut’s utilization review law (Conn. Gen. Stat. § 38a-591 et seq.), which establishes standards for utilization review processes, appeal timelines, and external review rights.
Connecticut requires that insurers provide access to external review by an Independent Review Organization (IRO) for adverse coverage decisions affecting services of $100 or more. For Connecticut pulmonary practices appealing Aetna denials for bronchoscopy, sleep diagnostics, biologic therapies, or pulmonary rehabilitation, the IRO process is a meaningful recovery pathway — particularly for medical necessity denials where the clinical evidence base is strong.
Aetna’s ASO plans in Connecticut are not subject to the Connecticut Insurance Department’s external review requirement, because ERISA governs self-funded plans. For denials from Aetna ASO plans, the available appeal pathways are internal appeals through Aetna’s ASO appeal process and, for certain claim disputes, ERISA-based litigation. This distinction matters for appeal strategy: practices should identify whether a denied claim is from a fully insured Aetna product (with Connecticut IRO access) or an ASO plan (without it) before determining the appeal pathway.
Aetna appeals that succeed in Connecticut share a consistent structure: they address Aetna’s specific denial rationale by citing the relevant Clinical Policy Bulletin, identifying the specific criteria the service meets, and providing documentation that fills the gap Aetna identified in the initial review. Generic appeals that argue clinical appropriateness without addressing Aetna’s policy criteria do not succeed at the rate that policy-specific appeals do.
The Connecticut Payer Mix Beyond Aetna
While Aetna is the dominant commercial payer in Connecticut, the state’s pulmonary billing landscape includes several other significant payer relationships that require payer-specific attention.
UnitedHealthcare in Connecticut
UnitedHealthcare maintains significant commercial enrollment in Connecticut, particularly in the Fairfield County and New Haven markets where large employers and financial services firms provide robust commercial coverage. UnitedHealthcare’s prior authorization requirements for pulmonary services differ from Aetna’s in ways that matter for Connecticut practices: UHC applies its own clinical coverage determination process through its Coverage Determination Guidelines, which are distinct from Aetna’s CPBs and may have different criteria for the same procedures.
UnitedHealthcare’s Gold Carding program — which exempts certain high-performing providers from prior authorization requirements for specific services — is available to Connecticut pulmonary providers who meet UHC’s quality and performance criteria. Practices that qualify for Gold Card status with UHC can reduce their authorization administrative burden significantly for the exempted procedure categories.
ConnectiCare and Local Market Plans
ConnectiCare, a Connecticut-based health plan now part of EmblemHealth, maintains a meaningful commercial and Medicare Advantage presence in the state. ConnectiCare’s prior authorization requirements and medical necessity criteria for pulmonary services reflect both its own clinical policies and its EmblemHealth parent’s utilization management framework. Connecticut pulmonary practices with significant ConnectiCare volume need to maintain ConnectiCare-specific authorization knowledge that is distinct from what they maintain for Aetna and UHC.
Connecticut Medicaid: HUSKY Health
Connecticut’s Medicaid program, branded as HUSKY Health, is administered through managed care for most beneficiaries. The primary HUSKY Health managed care organizations include Aetna Better Health of Connecticut, Anthem HealthKeepers Plus Connecticut, and Community Health Network of Connecticut. Each MCO has distinct prior authorization requirements for pulmonary services, and claims must be submitted to the correct MCO based on the patient’s specific HUSKY Health enrollment.
Connecticut Medicaid eligibility verification through the Connecticut Medical Assistance Program (CMAP) portal confirms both HUSKY Health eligibility and MCO enrollment. Practices that do not use CMAP for Medicaid eligibility verification — or that route all HUSKY Health claims to the state Medicaid program rather than the specific MCO — will encounter the same routing error pattern that creates revenue leakage for Medicaid practices in Massachusetts and New York.
Aetna Better Health of Connecticut’s authorization requirements for pulmonary services align with Aetna’s commercial policies in many respects but include HUSKY-specific coverage criteria that reflect Connecticut Medicaid’s benefit structure. A practice that applies Aetna’s commercial authorization standards to Aetna Better Health patients without confirming the HUSKY-specific requirements will encounter authorization gaps for services covered differently under the Medicaid plan.
Building an Aetna-Ready Billing Workflow for Connecticut Pulmonary Practices
A Connecticut pulmonary practice ready to manage Aetna billing effectively needs the following workflow elements:
- Aetna product type identification at eligibility verification. Confirm whether each Aetna patient is enrolled in a fully insured commercial product, an ASO plan, Medicare Advantage, or Aetna Better Health of Connecticut — and document the product type for authorization and appeal pathway decisions.
- Current Aetna CPB monitoring and authorization matrix. A staff member or billing partner responsible for monitoring Aetna’s Clinical Policy Bulletin updates and reflecting policy changes in the practice’s authorization reference matrix, reviewed quarterly at minimum.
- Biologic authorization documentation protocol. A pre-authorization checklist for each biologic therapy that collects all required documentation — biomarker results, step-therapy records, severity documentation, specialist attestation — before the authorization request is submitted.
- Post-encounter CPT-to-authorization reconciliation. Every claim reviewed against the Aetna authorization before submission to confirm that billed CPT codes are covered under the issued authorization, with a process for handling procedure scope changes during encounters.
- CMAP-based HUSKY Health MCO enrollment verification. Connecticut Medicaid patients verified through CMAP at scheduling to confirm MCO enrollment and correct claim routing.
- Appeal strategy differentiated by Aetna product type. Fully insured Aetna product denials pursued through Connecticut IRO external review when appropriate. ASO plan denials handled through Aetna’s internal process with awareness that Connecticut external review is not available.
How PulmoCare RCM Supports Connecticut Pulmonary Practices
PulmoCare RCM works exclusively with pulmonary and critical care practices. Our Connecticut billing workflows are built around Aetna’s Clinical Policy Bulletins, the distinctions between Aetna’s product lines, ConnectiCare’s coverage policies, and HUSKY Health managed care requirements — not generic commercial billing frameworks.
We start with an AR review that identifies your Aetna denial patterns by procedure, by product type, and by denial category — surfacing the specific documentation gaps, authorization errors, and workflow deficiencies that are driving your write-offs.
If your Connecticut pulmonary practice is experiencing Aetna authorization denials, medical necessity documentation challenges, or biologic therapy authorization delays, reach out to PulmoCare RCM for a complimentary consultation and AR review.